Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter.
In a report released yesterday, Luca Issi from RBC Capital maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report), with a ...
Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target of ...
FDA Clearance for the RESOLUTION Basket Trial in Rheumatology Trial Initiation Targeted for Mid-2025; Proof-of-Concept Data ...
Allogene Therapeutics Inc. (ALLO) on Thursday reported a loss of $59.9 million in its fourth quarter. On a per-share basis, the South San Francisco, California-based company said it had a loss of 28 ...
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream inf ...
The fresh funds will be used to expand clinics, invest in AI-driven healthcare, and enhance patient engagement, strengthening ...
Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support ...
Kingsway Drive East 957: Belinda M. Weston to Jasmine M. Ezeb, $265,000. Lafayette St. 632: W. Harvey III to Thomas L. Claverie, $125,000. Wall Blvd. 525: Ronald A. Gasser to Ronald A. Gasser, ...
Andy Allo poses at the premiere of the film "Number One on the Call Sheet" at the TCL Chinese Theatre on Wednesday, March 12, ...
Bengaluru-based Allo Health raises INR 16 Cr in Pre-Series A round led by Zerodha's Rainmatter to expand clinic network and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback